Boston Scientific Corp.
BSX
Market Cap$108.94B
Close$
Earnings Call Q4 2023
January 31, 2024 - AI Summary
Boston Scientific reported strong Q4 and full-year 2023 results, with operational sales growth of 15% in Q4 and 13% for the full year.
The company exceeded its financial goals for the year, with organic sales growth of 12% and adjusted EPS growth of 20%.
For 2024, Boston Scientific expects organic revenue growth of 8% to 9%, driven by ongoing momentum across its business units and regions.
Exclusive for Stockcircle Pro members
Sign up
$28.32
62% downside
Current Fair Value
62% downsideOvervalued by 62% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $108.94 Billion |
|---|---|
| Enterprise Value | $117.23 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $1.2 |
| Beta | 0.49 |
| Outstanding Shares | 1,470,179,843 |
| Avg 30 Day Volume | 7,246,230 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 61.72 |
|---|---|
| PEG | 94.96 |
| Price to Sales | 7.45 |
| Price to Book Ratio | 5.73 |
| Enterprise Value to Revenue | 7.97 |
| Enterprise Value to EBIT | 46.39 |
| Enterprise Value to Net Income | 66 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.53 |
Revenue Sources
No data
ESG Score
No data
About Boston Scientific Corp.
2,020 employees
CEO: Michael Mahoney